Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck.
Bottom Line: The 2-year DSS for patients treated with APF-C was 96.7% [95% Confidence Interval (CI): 85.2%, 99.8%] and with TPF-C was 77.6% (CI: 62.6%, 89.7%) (P = 0.0004).In p16 positive OPSCC, the 2-year DSS for APF-C was 100% and for TPF-C was 74.6% (CI: 47.4%, 94.6%) (P = 0.0019) and the 2-year OS for APF-C was 94.1% (CI: 65.0%, 99.2%) and for TPF-C was 74.6% (CI: 39.8%, 91.1%) (P = 0.013).A 2-year DSS and OS were significantly better with a nab-paclitaxel-based IC regimen (APF-C) compared to a docetaxel-based IC regimen (TPF-C) in p16-positive OPSCC.
Affiliation: Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.Show MeSH
Related in: MedlinePlus
Mentions: Causes of death are shown in Table4. Disease progression resulting in death was more common in the TPF-C group (39%) compared to the APF-C group (3%). A competing risks model (Gray's test) 9 was used to differentiate deaths due to disease progression from other causes of death without censoring deaths of other causes. This model showed that the incidence of death due to disease progression was greater in the TPF-C group compared to the APF-C group (P = 0.0004). The hazard of death due to disease progression is 94% lower in the APF-C group than in the TPF-C group (HR = 0.060 [CI: 0.008, 0.45]). There was no difference in the hazard ratios of TRM or death of other causes (second malignancy and noncancer death) in the two treatment groups (TRM:HR = 0.632 [CI: 0.057, 6.97]); death of other causes [HR = 0.701 (CI: 0.116, 4.24)] (Fig.2).
Affiliation: Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.